tirzepatide serotonin Interaction of serotonin/GLP-1 circuitry in a dual preclinical model for psychiatric disorders and metabolic dysfunction Evaluating the antidepressant effects of...

Enrollment will begin in November 2025 and is expected to be completed by May 2026

The other is noticing palpitations on a weekly basis

Large-scale randomised controlled trials of GLP-1 agonists, including cardiovascular outcome studies involving tens of thousands of participants, have not demonstrated an increased risk of suicidal ideation or behaviour compared with placebo

Retatrutide for simultaneous GLP-1, GIP, and glucagon receptor engagement in metabolic regulation research

Retatrutide (5mg-10mg), Triple Incretin Receptor Agonist Engineered Engagement of GLP-1, GIP, and Glucagon Receptors Introduction Engineered Engagement of GLP-1, GIP, and Glucagon Receptors Retatrutide is a synthetic 39-residue peptide engineered as a balanced agonist of three distinct class B G protein-coupled receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR)

Mounjaro and Ozempic are two of the leading GLP-1 medications for the treatment of type 2 diabetes